Heritage Wealth Advisors Increases Stake in Johnson & Johnson (NYSE:JNJ)

Heritage Wealth Advisors increased its position in shares of Johnson & Johnson (NYSE:JNJ) by 3.5% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 338,120 shares of the company’s stock after buying an additional 11,492 shares during the period. Johnson & Johnson comprises about 2.8% of Heritage Wealth Advisors’ portfolio, making the stock its 13th biggest position. Heritage Wealth Advisors’ holdings in Johnson & Johnson were worth $56,074,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in JNJ. Elios Financial Group Inc. lifted its position in shares of Johnson & Johnson by 1.5% during the 1st quarter. Elios Financial Group Inc. now owns 4,496 shares of the company’s stock worth $746,000 after buying an additional 66 shares during the last quarter. Atlantic Family Wealth LLC raised its stake in Johnson & Johnson by 4.4% during the 1st quarter. Atlantic Family Wealth LLC now owns 1,603 shares of the company’s stock worth $266,000 after acquiring an additional 67 shares in the last quarter. MBA Advisors LLC lifted its position in Johnson & Johnson by 1.2% in the first quarter. MBA Advisors LLC now owns 5,553 shares of the company’s stock valued at $921,000 after acquiring an additional 68 shares during the last quarter. Sovereign Financial Group Inc. boosted its stake in Johnson & Johnson by 1.8% in the first quarter. Sovereign Financial Group Inc. now owns 3,928 shares of the company’s stock valued at $651,000 after acquiring an additional 69 shares in the last quarter. Finally, Nabity Jensen Investment Management Inc grew its holdings in shares of Johnson & Johnson by 1.5% during the first quarter. Nabity Jensen Investment Management Inc now owns 4,624 shares of the company’s stock worth $767,000 after purchasing an additional 69 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Johnson & Johnson Price Performance

Shares of JNJ opened at $164.76 on Friday. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50. The stock’s 50 day moving average is $157.18 and its two-hundred day moving average is $156.44. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99. The firm has a market capitalization of $396.81 billion, a PE ratio of 17.62, a P/E/G ratio of 2.13 and a beta of 0.41.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%. The business had revenue of $23.74 billion during the quarter, compared to analysts’ expectations of $22.85 billion. During the same period last year, the firm earned $2.82 EPS. The company’s quarterly revenue was up 5.8% compared to the same quarter last year. Research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be paid a $1.30 dividend. The ex-dividend date is Tuesday, August 26th. This represents a $5.20 annualized dividend and a dividend yield of 3.2%. Johnson & Johnson’s dividend payout ratio (DPR) is 55.61%.

Analysts Set New Price Targets

Several analysts have recently weighed in on JNJ shares. Wall Street Zen downgraded Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a report on Friday, July 18th. UBS Group boosted their price objective on Johnson & Johnson from $180.00 to $190.00 and gave the company a “buy” rating in a research note on Thursday, July 17th. Royal Bank Of Canada raised their target price on shares of Johnson & Johnson from $181.00 to $185.00 and gave the stock an “outperform” rating in a research report on Thursday, July 17th. The Goldman Sachs Group upgraded shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and upped their price target for the company from $157.00 to $172.00 in a research report on Wednesday, April 9th. Finally, Morgan Stanley raised their price objective on shares of Johnson & Johnson from $171.00 to $176.00 and gave the stock an “equal weight” rating in a research report on Thursday, July 17th. Nine research analysts have rated the stock with a hold rating, ten have given a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $174.50.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.